

Welcome to the Integrated Research Application System

IRAS Project Filter

The integrated dataset required for your project will be created from the answers you give to the following questions. The system will generate only those questions and sections which (a) apply to your study type and (b) are required by the bodies reviewing your study. Please ensure you answer all the questions before proceeding with your applications.

Please complete the questions in order. If you change the response to a question, please select 'Save' and review all the questions as your change may have affected subsequent questions.

Please enter a short title for this project (maximum 70 characters)
HORIZONS: Understanding the impact of cancer diagnosis and treatment

1. Is your project research?

Yes No

2. Select one category from the list below:

- Clinical trial of an investigational medicinal product
- Clinical investigation or other study of a medical device
- Combined trial of an investigational medicinal product and an investigational medical device
- Other clinical trial to study a novel intervention or randomised clinical trial to compare interventions in clinical practice
- Basic science study involving procedures with human participants
- Study administering questionnaires/interviews for quantitative analysis, or using mixed quantitative/qualitative methodology
- Study involving qualitative methods only
- Study limited to working with human tissue samples (or other human biological samples) and data (specific project only)
- Study limited to working with data (specific project only)
- Research tissue bank
- Research database

If your work does not fit any of these categories, select the option below:

Other study

2a. Please answer the following question(s):

- a) Does the study involve the use of any ionising radiation? Yes No
- b) Will you be taking new human tissue samples (or other human biological samples)? Yes No
- c) Will you be using existing human tissue samples (or other human biological samples)? Yes No

3. In which countries of the UK will the research sites be located? *(Tick all that apply)*

- England
- Scotland

- Wales
 Northern Ireland

3a. In which country of the UK will the lead NHS R&D office be located:

- England
 Scotland
 Wales
 Northern Ireland
 This study does not involve the NHS

4. Which applications do you require?

IMPORTANT: If your project is taking place in the NHS and is led from England select 'IRAS Form'. If your project is led from Northern Ireland, Scotland or Wales select 'NHS/HSC Research and Development Offices' and/or relevant Research Ethics Committee applications, as appropriate.

- IRAS Form
 Confidentiality Advisory Group (CAG)
 National Offender Management Service (NOMS) (Prisons & Probation)

For NHS/HSC R&D Offices in Northern Ireland, Scotland and Wales the CI must create NHS/HSC Site Specific Information forms, for each site, in addition to the study wide forms, and transfer them to the PIs or local collaborators.

For participating NHS organisations in England different arrangements apply for the provision of site specific information. Refer to IRAS Help for more information.

Most research projects require review by a REC within the UK Health Departments' Research Ethics Service. Is your study exempt from REC review?

- Yes No

5. Will any research sites in this study be NHS organisations?

- Yes No

5a. Are all the research costs and infrastructure costs (funding for the support and facilities needed to carry out research e.g. NHS Support costs) for this study provided by a NIHR Biomedical Research Centre, NIHR Biomedical Research Unit, NIHR Collaboration for Leadership in Health Research and Care (CLAHRC), NIHR Patient Safety Translational Research Centre or a Diagnostic Evidence Co-operative in all study sites?

Please see information button for further details.

- Yes No

Please see information button for further details.

5b. Do you wish to make an application for the study to be considered for NIHR Clinical Research Network (CRN) Support and inclusion in the NIHR Clinical Research Network Portfolio?

Please see information button for further details.

- Yes No

The NIHR Clinical Research Network provides researchers with the practical support they need to make clinical studies happen in the NHS e.g. by providing access to the people and facilities needed to carry out research "on the ground".

If you select yes to this question, you must complete a NIHR Clinical Research Network (CRN) Portfolio Application Form (PAF) immediately after completing this project filter question and before submitting other applications. Failing to complete the PAF ahead of other applications e.g. HRA Approval, may mean that you will be unable to access NIHR CRN Support for your study.

6. Do you plan to include any participants who are children?

Yes No

7. Do you plan at any stage of the project to undertake intrusive research involving adults lacking capacity to consent for themselves?

Yes No

Answer Yes if you plan to recruit living participants aged 16 or over who lack capacity, or to retain them in the study following loss of capacity. Intrusive research means any research with the living requiring consent in law. This includes use of identifiable tissue samples or personal information, except where application is being made to the Confidentiality Advisory Group to set aside the common law duty of confidentiality in England and Wales. Please consult the guidance notes for further information on the legal frameworks for research involving adults lacking capacity in the UK.

8. Do you plan to include any participants who are prisoners or young offenders in the custody of HM Prison Service or who are offenders supervised by the probation service in England or Wales?

Yes No

9. Is the study or any part of it being undertaken as an educational project?

Yes No

10. Will this research be financially supported by the United States Department of Health and Human Services or any of its divisions, agencies or programs?

Yes No

11. Will identifiable patient data be accessed outside the care team without prior consent at any stage of the project (including identification of potential participants)?

Yes No

NOTICE OF SUBSTANTIAL AMENDMENT

*Please use this form to notify the main REC of substantial amendments to all research other than clinical trials of investigational medicinal products (CTIMPs).
The form should be completed by the Chief Investigator using language comprehensible to a lay person.*

Details of Chief Investigator:

	Title	Forename/Initials	Surname
	Professor	Claire	Foster
Work Address	Faculty of Health Sciences, Building 67 Highfield Campus, University of Southampton University Road, Southampton		
PostCode	SO17 1BJ		
Email	C.L.Foster@soton.ac.uk		
Telephone	02380 594006		
Fax			

Full title of study:	HORIZONS: a cohort study to explore recovery of health and well-being in adults diagnosed with cancer
Lead sponsor:	University Hospital Southampton NHS Foundation Trust
Name of REC:	North West - Lancaster Research Ethics Committee
REC reference number:	16/NW/0425
Name of lead R&D office:	University Hospital Southampton NHS Foundation Trust
Date study commenced:	REC approval 20/06/2016 Currently under HRA review
Protocol reference (if applicable), current version and date:	1.0 05/05/2016
Amendment number and date:	1 15/07/2016

Type of amendment

(a) Amendment to information previously given in IRAS

Yes No

If yes, please refer to relevant sections of IRAS in the "summary of changes" below.

Filter question 3 "In which countries in the UK will the research sites be located" addition to include Wales and Northern Ireland

A71-2, "where will the research take part", addition to include Wales and Northern Ireland"

A72, "Which organisations in the UK will host the research", addition to include NHS Organisations in Wales and HSC organisations in Northern Ireland

Part C, update to include 16 additional research sites following the completion of the pilot phase, please see HORIZONS phase 2 sites and part C updated

(b) Amendment to the protocol

Yes No

If yes, please submit either the revised protocol with a new version number and date, highlighting changes in bold, or a document listing the changes and giving both the previous and revised text.

(c) Amendment to the information sheet(s) and consent form(s) for participants, or to any other supporting documentation for the study

Yes No

If yes, please submit all revised documents with new version numbers and dates, highlighting new text in bold.
 HORIZONS - PIS V1.1 05.07.2016 (clean and tracked changes)

Is this a modified version of an amendment previously notified and not approved?

Yes No

Summary of changes

Briefly summarise the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study.

If this is a modified amendment, please explain how the modifications address the concerns raised previously by the ethics committee.

If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained.

1. We have previously submitted the HORIZONS baseline measures (as individual measures) and we are now able to submit the pilot phase baseline questionnaire. This questionnaire is a collation of the measures which have been reviewed and approved previously.
2. Through the HRA approval process we have been requested to make some minor changes to the PIS regarding data transfer and retention. Although these are deemed non-substantial we submit these to you for reference, HORIZONS - PIS V1.1 05.07.2016 clean and tracked changes versions
3. We are also now in a position to add 16 additional sites which we would like to open at the end of the pilot phase, in September/October. Again we appreciate this is deemed a non-substantial amendment for a non-CTIMP but we submit it under this amendment for reference, summarised in the attached "HORIZONS phase 2 sites"

Any other relevant information

Applicants may indicate any specific issues relating to the amendment, on which the opinion of a reviewing body is sought.

List of enclosed documents

<i>Document</i>	<i>Version</i>	<i>Date</i>
HORIZONS - PIS (clean)	1.1	05/07/2016
HORIZONS - PIS (tracked changes)	1.1	05/07/2016
HORIZONS 202342 REC 16 NW 0425 SA1 cover letter	1	18/07/2016
HORIZONS phase 2 sites	1	18/07/2016
HORIZONS 202342 baseline questionnaire Pilot v1.0_BREAST	1.0	07/07/2016
HORIZONS 202342 baseline questionnaire Pilot v1.0_GYNAE	1.0	07/07/2016
HORIZONS 202342 baseline questionnaire Pilot v1.0_NHL	1.0	07/07/2016

Declaration by Chief Investigator

1. *I confirm that the information in this form is accurate to the best of my knowledge and I take full responsibility for it.*
2. *I consider that it would be reasonable for the proposed amendment to be implemented.*

This section was signed electronically by Professor Claire Foster on 18/07/2016 13:54.

Job Title/Post: Director of Macmillan Survivorship Research Group
Organisation: University of Southampton
Email: c.l.foster@soton.ac.uk

Declaration by the sponsor's representative

I confirm the sponsor's support for this substantial amendment.

This section was signed electronically by Mrs Sharon Davies-Dear on 19/07/2016 07:59.

Job Title/Post: Research Governance Officer
Organisation: University Hospital Southampton NHS Foundation Trust
Email: sharon.davies-dear@uhs.nhs.uk